Hospitals are beginning to use a new, more potent weapon against
sepsis, the devastating condition that kills more than 25 percent of its
victims and costs hospitals billions of dollars annually. In the U.S.
alone, more than a million people become infected each year, and it
contributes to as many half of all deaths in hospitals.
Last fall, the U.S. Food and Drug Administration approved the new technology, developed by T2 Biosystems, for diagnosing sepsis caused by a fungus called
Candida. Several hospitals have begun deploying T2’s
Candida-detection
system, which is based on the same physical principle behind magnetic
resonance imaging. By the end of this year the company aims to have 30
hospitals signed on to purchase and use the technology.
Sepsis is a destructive reaction to an infection marked by an
overwhelming inflammatory response throughout the body. If left
untreated, sepsis can cause organ malfunction and death. Treating a
septic patient requires pinpointing the bacterial or fungal organism
that is the root cause. Today that process takes at least a day, and can
take up to five days, as the patient’s condition worsens. T2 Biosystems
says its novel pathogen detector, called T2 Magnetic Resonance (T2MR),
can identify the bug within five hours.
Doctors typically give a septic patient an immediate dose of a
so-called broad-spectrum antibiotic that kills a variety of different
bacteria, and then try to figure out the specific bug at fault by
drawing blood and performing a lab test called a blood culture. At that
point it is a race against the unidentified pathogen, and the blood
culture step, which often doesn’t work, simply takes too long, says T2
Biosystems CEO John McDonough. McDonough cites clinical data that
implies that if patients can get the right drug within 12 hours of first
showing symptoms, the chance of death can be cut in half. “Every hour
of delayed therapy increases mortality by 7 to 8 percent,” he says.
Broad-spectrum antibiotics often don’t work, and are useless against
fungal sepsis, which is even more deadly than bacterial sepsis.
Candida infections in the bloodstream kill some 40 percent of patients.
“We have the only technology we’re aware of that can go directly from
a blood sample to a species-specific diagnostic test result,” says
McDonough. It’s also more accurate than a blood culture. In a recent head-to-head comparison involving 55 patients known to have
Candida infections, T2MR detected the pathogen in 96 percent of the patients, whereas blood culture detected it in only 60 percent.
The T2MR detector works by measuring changes in the magnetic
properties of the water molecules in the sample. After some processing
steps, magnetic nanoparticles, equipped on their surface with strands of
DNA complementary to strands in the target pathogen, are mixed with the
sample. If a given target is present, the particles will attach to it
and cluster, causing changes in the magnetic properties of the water
molecules in the sample. Applying magnetic pulses elicits a response
from those molecules, called T2 relaxation, and by measuring the change
in this signal, the device automatically determines whether or not a
given bug is present.
Six hospitals have begun using the Candida diagnostic test, and 13
more have signed contracts to adopt the technology. Next in the pipeline
is a bacteria detector aimed at the bugs not covered by broad-spectrum
antibiotics. The company expects to begin testing the bacteria detector
in clinical trials by the end of this year. If it can get FDA-approval
for this test as quickly as it did for the Candida test, the bacteria
diagnostic could be in the market as early as 2017.
